Resource Summary Report

Generated by RRID on Aug 27, 2026

MDA-PCa-2b

RRID:CVCL_4748
Type: Cell Line

Proper Citation

ATCC Cat# CRL-2422, RRID:CVCL_4748

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4748

Proper Citation: ATCC Cat# CRL-2422, RRID:CVCL_4748

Description: Cell line MDA-PCa-2b is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: PMID:9815652, PMID:12725112, PMID:14518029, PMID:14518030, PMID:15486987, PMID:22460905, PMID:23671654, PMID:30787054, PMID:30894373, PMID:31068700, PMID:31395879

Comments: Population: African American., Part of: TCGA-110-CL cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-PCa-2b

Synonyms: MDA PCa 2b, MDAPCa-2b, MDAPCa2b, MDAPCA2B, MDAPC2B, MDA2B, M.D. Anderson-Prostate Cancer-2b

Cross References: BTO:BTO_0005050, CLO:CLO_0007629, ArrayExpress:E-MTAB-2770, ATCC:CRL-2422, BioSample:SAMN03471841, BioSample:SAMN10988222, cancercelllines:CVCL_4748, Cell_Model_Passport:SIDM01664, Cosmic:1689712, Cosmic:2651771, Cosmic:2669171, DepMap:ACH-000952, GEO:GSM91928, GEO:GSM648821, GEO:GSM887302, GEO:GSM888377, IARC_TP53:30117, LiGeA:CCLE_281, PharmacoDB:MDAPCa2b_896_2019, Progenetix:CVCL_4748,

Wikidata:Q54904655

ID: CVCL_4748

Vendor: ATCC

Catalog Number: CRL-2422

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260815T234601+0000

Ratings and Alerts

No rating or validation information has been found for MDA-PCa-2b.

No alerts have been found for MDA-PCa-2b.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Tsui M, et al. (2026) Landscape of Allele-Specific Expression in Prostate Cancer Reveals Recurrent, Stage-Specific Events in AR Signaling and Resistance Pathways. Molecular cancer research : MCR, 24(4), 242.

Cunningham ML, et al. (2026) PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer. Molecular oncology, 20(2), 369.

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. Cellular signalling, 141, 112368.

Badal S, et al. (2025) Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients. Cancer research communications, 5(10), 1758.

Li S, et al. (2025) Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer. bioRxiv : the preprint server for biology.

Shah K, et al. (2025) Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(13), 2824.

Khan S, et al. (2025) Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy. International journal of molecular sciences, 26(24).

Ganapathy K, et al. (2025) Reciprocal regulation between DNMT3A/3B and microRNAs miRs-299-3p/-30e is a causal factor for the downregulation of microRNAs targeting androgen receptor in prostate cancer. Heliyon, 11(3), e41948.

Xiang RR, et al. (2025) CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. Cell reports, 44(2), 115312.

Vellky JE, et al. (2024) ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(8), 1530.

Van Goubergen J, et al. (2024) Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression. Molecular oncology.

Sandor LF, et al. (2024) De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis. Cell reports, 43(3), 113936.

Xu Y, et al. (2024) ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer discovery, 14(8), 1496.

Skidmore LK, et al. (2024) Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics, 23(12), 1842.

Sen A, et al. (2024) Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. Molecular oncology.

Schatz CA, et al. (2024) Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(11), 2531.

Xu Y, et al. (2023) ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. bioRxiv : the preprint server for biology.

Ganapathy K, et al. (2022) Anticancer function of microRNA-30e is mediated by negative regulation of HELLPAR, a noncoding macroRNA, and genes involved in ubiquitination and cell cycle progression in prostate cancer. Molecular oncology, 16(16), 2936.

Hasan MF, et al. (2021) LncRNA PAINT is associated with aggressive prostate cancer and dysregulation of cancer hallmark genes. International journal of cancer.

Harris KS, et al. (2021) CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance. Scientific reports, 11(1), 1465.